RxDoctor Payments Data

Andreas Stefan, MD

Gastroenterology · Portland, MENPI 1831299460

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Boston Scientific at 34.1% of the total. 2025 is the largest year on record at $787, 8.2 times the $97 reported in 2019.

$2,376in general payments, 2019–2025

Across 53 payments — averaging $44.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$811
  • Cook Medical LLC$372
  • Fujifilm Healthcare Americas Corporation$221
  • Steris Corporation$155
  • AbbVie$127
  • Janssen Scientific Affairs, LLC$122
  • plus $569 from 13 others

What the payments were for

  • Food & beverage$2,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,376 in reported general payments places this provider in the 70th percentile of 68 gastroenterology providers in Maine.

See all gastroenterology providers in Maine

Medicare billing

Part B allowed, 2024
$220,377
Medicare patients
327
Services billed
7,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab23$632,054
CreonLipase/Protease/Amylase27$125,676
Mesalamine24$15,498
LinzessLinaclotide15$11,408
Ursodiol34$7,299
Omeprazole72$1,487
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl71$871
Colestipol Hcl14$691
Pantoprazole Sodium44$269
Acetaminophen-CodeineAcetaminophen With Codeine12$222
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl17$189
Metoclopramide Hcl11$153
Prednisone14$135
Ondansetron OdtOndansetron11$98
Famotidine13$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$105$632,05423 claims
AbbVieCreon, Linzess$127$137,08442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 gastroenterology providers in Maine.

Other gastroenterology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →